Navigation Links
DrugRisk Update: Byetta Maker Agrees With Transferring Lawsuits to Federal Court
Date:5/14/2013

Sacramento, CA (PRWEB) May 14, 2013

The diabetes drug safety advocates at DrugRisk.com are announcing updated information for patients who have taken the medication Byetta. The maker of the drug has agreed with moving the growing number of injury claims to a special federal court in California*.

DrugRisk was created to improve the safety of those taking popular prescription drugs by providing the latest warnings, recalls, studies and legal news. Patients can see if others are experiencing similar side effects and decide if they need legal advice.

Byetta is a twice-daily injectable medication released in 2005 to help those with type-2 diabetes control blood sugar. It generated sales of over $300 million last year, when it was purchased with Amylin Pharmaceuticals by Bristol-Myers Squibb**.

However, DrugRisk has added a 2011 study from UCLA indicating Byetta could increase the risk of pancreatic cancer by 290% and thyroid cancer by 473%***. The Journal for the American Medical Association also recently warned these drugs can double the risk of pancreatitis, a major risk factor for pancreatic cancer****.

Due to the number of patients filing a Byetta lawsuit alleging cancer, lawyers have asked that cases be consolidated to a special federal multi-district court in California*****. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452, United States Judicial Panel on Multidistrict Litigation).

Now, DrugRisk has learned that Amylin and Eli Lilly have filed a response agreeing to the transfer to the federal court*. The resource center believes this could expedite the legal process for both the companies and patients alleging injury.

Anyone affected by cancer after taking Byetta is encouraged to speak with a lawyer about their legal options. However, due to the specialized nature of federal drug injury cases, DrugRisk only recommends lawyers who have already handled Byetta lawsuits.

For more information on the research, side effects and litigation news related to Byetta and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.

*JPML, 4/29/13; cdn.aboutlawsuits.com/wp-content/uploads/2013-04-29-Amylin-MDL-Response.pdf
**Bloomberg, 2/25/13; bloomberg.com/news/2013-02-25/merck-bristol-diabetes-drugs-linked-to-pancreatitis-risk.html
***Gastroenterology, July 2011; ctsi.ucla.edu/education/files/publicview/training/docs/FDA-analysis.pdf
****JAMA Internal Medicine, 2/25/13; archinte.jamanetwork.com/article.aspx?articleid=1656537
*****JPML, 4/5/13; cdn.aboutlawsuits.com/wp-content/uploads/2013-04-05-Incretin-Mimetics-MDL.pdf

Read the full story at http://www.prweb.com/releases/2013-byetta-pancreatic/cancer-lawsuit/prweb10728764.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. DrugRisks Update: Warning Added to Pradaxa For Blood Condition
2. DrugRisks Update: Use of NuvaRing Drops Amid Injury Allegations
3. DrugRisk Update: New Study Warns of Cancer in Byetta Side Effects
4. DrugRisk Adds New Pancreatic Cancer Warning for Diabetes Drug Januvia
5. DrugRisks News Update: Bayer Loses Yaz Patent as Blood Clot Settlements Continue
6. DrugRisk Update: Court Asks for Pradaxa Lawsuit Test Cases
7. DrugRisks Adds Update From Court Ordering Mediation of Stryker Hip Lawsuits
8. DrugRisk Announces Launch of Byetta Cancer Resource Center
9. DrugRisks Update: Federal Court Schedules First Mirena Lawsuit Hearing
10. DrugRisk Announces Addition of Januvia Cancer Resource Center
11. DrugRisks Legal Update: Jury to Decide Actos Cancer Trial This Week
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... ... As health professionals work to improve their approach to healthcare, there is ... than filling out a survey; in many cases health professionals and patients are working ... and research on the importance of active engagement with patients and members of the ...
(Date:10/13/2017)... , ... October 13, 2017 ... ... of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ... on guideline updates for the primary prevention of cardiovascular diseases during the ...
(Date:10/13/2017)... ... , ... Ellevate Network, the leading network for professional women, brought together some ... at their inaugural Summit in New York City in June. The event was livestreamed ... over 3 million. To watch the Mobilize Women video, click here . ...
(Date:10/13/2017)... ... 2017 , ... “The Journey: From the Mountains to the Mission Field”: the ... in the Philippines. “The Journey: From the Mountains to the Mission Field” is the ... She has taught all ages and currently teaches a class of ladies at her ...
(Date:10/12/2017)... WAUSAU, Wis. (PRWEB) , ... October 12, 2017 ... ... formulated standard products to meet the demand of today’s consumer and regulatory authorities ... team of probiotic experts and tested to meet the highest standard. , ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), ... call and webcast on Friday, November 3, 2017, beginning ... ending at approximately 8:30 a.m. (CDT) / 9:30 a.m. ... 2017 financial performance and guidance for 2018, Hill-Rom executives ... enhance operational performance, and long-range financial outlook through 2020. ...
(Date:9/25/2017)... Sept. 25, 2017   Montrium , an ... solutions, today—from the IQPC Trial Master Files & ... NL)—announced that EastHORN Clinical Services has selected ... and TMF management. EastHORN, a leading European contract ... to increase transparency to enable greater collaboration with ...
(Date:9/22/2017)... DIEGO , Sept. 22, 2017 AVACEN ... medical device is now successfully helping those with the ... Fibromyalgia diagnosed Amanda in Essex, ... dressed and washing my hair, experiencing no sleep at ... in painful spasm… I cannot recommend [the AVACEN 100] ...
Breaking Medicine Technology: